| Literature DB >> 26317989 |
Laura Brugnara1, Roger Mallol2, Josep Ribalta3, Maria Vinaixa4, Serafín Murillo1, Teresa Casserras5, Montse Guardiola3, Joan Carles Vallvé3, Susana G Kalko5, Xavier Correig4, Anna Novials1.
Abstract
Patients with type 1 diabetes (T1D) present increased risk of cardiovascular disease (CVD). The aim of this study is to improve the assessment of lipoprotein profile in patients with T1D by using a robust developed method 1H nuclear magnetic resonance spectroscopy (1H NMR), for further correlation with clinical factors associated to CVD. Thirty patients with T1D and 30 non-diabetes control (CT) subjects, matched for gender, age, body composition (DXA, BMI, waist/hip ratio), regular physical activity levels and cardiorespiratory capacity (VO2peak), were analyzed. Dietary records and routine lipids were assessed. Serum lipoprotein particle subfractions, particle sizes, and cholesterol and triglycerides subfractions were analyzed by 1H NMR. It was evidenced that subjects with T1D presented lower concentrations of small LDL cholesterol, medium VLDL particles, large VLDL triglycerides, and total triglycerides as compared to CT subjects. Women with T1D presented a positive association with HDL size (p<0.005; R = 0.601) and large HDL triglycerides (p<0.005; R = 0.534) and negative (p<0.005; R = -0.586) to small HDL triglycerides. Body fat composition represented an important factor independently of normal BMI, with large LDL particles presenting a positive correlation to total body fat (p<0.005; R = 0.505), and total LDL cholesterol and small LDL cholesterol a positive correlation (p<0.005; R = 0.502 and R = 0.552, respectively) to abdominal fat in T1D subjects; meanwhile, in CT subjects, body fat composition was mainly associated to HDL subclasses. VO2peak was negatively associated (p<0.005; R = -0.520) to large LDL-particles only in the group of patients with T1D. In conclusion, patients with T1D with adequate glycemic control and BMI and without chronic complications presented a more favourable lipoprotein profile as compared to control counterparts. In addition, slight alterations in BMI and/or body fat composition showed to be relevant to provoking alterations in lipoproteins profiles. Finally, body fat composition appears to be a determinant for cardioprotector lipoprotein profile.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26317989 PMCID: PMC4552656 DOI: 10.1371/journal.pone.0136348
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Network models of lipoproteins and clinical variables in control subjects and in T1D subjects.
Control (1A) and T1D subjects (1B). Integration of datasets was accomplished with the Cytoscape tool (www.cytoscape.org), which constructs and displays correlation networks between components (p-value < 0.005 and thresholds R > ± 0.5 for clinical variables, and R > ± 0.7 for lipoprotein variables). Continuous lines represent positive correlations, and dashed lines represent negative associations. Grey spheres represent clinical variables; in red, LDL related lipoproteins; in green, HDL lipoproteins; in blue, VLDL lipoproteins; and in purple, total triglycerides. Orange circles mark the variables that are reduced in T1D subjects.
Clinical characteristics of subjects with type 1 diabetes and controls.
| Type 1 diabetes (n = 30) | Controls (n = 30) | |
|---|---|---|
|
| 10 / 20 | 10 / 20 |
|
| 34.8 ± 9.6 | 35.8 ± 8.8 |
|
| ||
| | 23.7 ± 2.8 | 23.2 ± 2.4 |
| | 81.5 ± 9.1 | 82 ± 8.4 |
| | 0.82 ± 0.06 | 0.82 ± 0.08 |
| | 24.7 ± 9.2 | 26 ± 8.8 |
| | 27.1 ± 11.8 | 29.8 ± 10.4 |
|
| ||
| | 15 | 21 |
| | 3008 ± 2230 | 2115 ± 1728 |
| | 33.5 ± 11.3 | 33.1 ± 9.1 |
|
| ||
| | 5 | 3 |
| | 8 | 4 |
| | 11.9 ± 10.1 | - |
| | 5 | - |
| | 7.05 ± 1.1 | - |
MET: Metabolic Equivalent of Task. 1 MET = 3.5 ml O2·kg−1·min−1. No statistical differences between groups, based on Chi-square and Student T-test.
Diet components by dietary records in subjects with type 1 diabetes and controls.
| Type 1 diabetes (n = 19) | Controls (n = 19) | p | |
|---|---|---|---|
|
| 5 / 14 | 6 / 13 | ns |
|
| 2215 ± 489 | 2430 ± 641 | ns |
|
| 101.2 ± 22.1 | 100.1 ± 28.9 | ns |
|
| 112 ± 27.1 | 112.5 ± 33.2 | ns |
| | 33.6 ± 10.3 | 35.4 ± 14.5 | ns |
| | 52.4 ± 13.7 | 51.3 ± 13.5 | ns |
| | 15.8 ± 5.5 | 16.6 ± 5.3 | ns |
| | 327.1 ± 122.8 | 351.7 ± 175.3 | ns |
|
| 193.2 ± 61.9 | 238.1 ± 72.4 |
|
| | 83.6 ± 32.3 | 103.4 ± 37.2 | ns (0.089) |
|
| 21.9 ± 7.1 | 22.2 ± 10.3 | ns |
|
| 3.7 ± 7 | 9 ± 10 | ns (0.069) |
No statistical differences between groups, based on Student T-test, except for total carbohydrate intake.
Statistical analysis of covariance contrasting lipid and lipoprotein data from subjects with type 1 diabetes and control subjects.
| Lipoprotein | FC | p-value |
|---|---|---|
|
| -1.44 | 0.0216477 |
|
| -1.26 | 0.0289017 |
|
| -1.21 | 0.0327273 |
|
| -1.06 | 0.0490274 |
a lipoprotein subfraction determined by LipoProfile
b lipoproteins subfraction determined PLS regression
c lipoprotein determined by conventional determinations
Covariates considered: age, gender, active smoking, waist/hip ratio, total fat percentage by DXA and VO2peak
* FC: Fold change. Negative values correspond to lower concentrations found in T1D.
Association of clinical characteristics and lipoproteins features in subjects with type 1 diabetes (T1D).
|
| Gender (+ for women) | BMI (kg/m2) | Abdominal fat % (DXA) | Total fat % (DXA) | VO2peak (mL/kg/min) |
|---|---|---|---|---|---|
|
| |||||
|
| - | - | - | 0.505 | -0.520 |
|
| - | -0.627 | - | - | - |
|
| 0.601 | - | - | - | - |
|
| |||||
|
| - | - | 0.502 | - | - |
|
| - | - | 0.552 | - | - |
|
| 0.534 | - | - | - | - |
|
| -0.586 | - | - | - | - |
|
| |||||
|
| - | -0.564 | - | - | - |
Summary of the main clinical variables and lipoprotein features that reached R ≥ ± 0.5 and p value < 0.005. Other clinical variables did not reach R ≥ ± 0.5: age, physically active profile, METs, active smoking, HbA1c or eGDR.
Association of clinical characteristics and lipoproteins in control subjects.
|
| Age (years) | Gender (+ for women) | Waist (cm) | Waist/Hip ratio |
|---|---|---|---|---|
|
| ||||
|
| - | - | -0.525 | -0.724 |
|
| 0.517 | - | - | 0.500 |
|
| - | - | -0.570 | -0.719 |
|
| ||||
|
| - | - | -0.554 | -0.683 |
|
| - | - | -0.600 | -0.737 |
|
| - | - | -0.583 | -0.711 |
|
| - | 0.524 | -0.598 | -0.680 |
|
| - | - | - | 0.595 |
|
| ||||
|
| - | - | - | -0.656 |
Summary of the clinical variables and lipoprotein features that reached R ≥ ± 0.5 and p value < 0.005. Other clinical variables did not reach R ≥ ± 0.5: Physically active profile, METs, VO2peak, active smoking, BMI, total fat percentage (DXA), abdominal fat (DXA).